logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Alejo Rodríguez-Vida

Hospital del Mar Research Institute
H指数:32
被引数:6,014

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune checkpoint inhibitor-related myocarditis, myositis, and myasthenia gravis overlap syndrome: a single-center case series and systematic review

免疫检查点抑制剂相关心肌炎、肌炎和重症肌无力重叠综合征：单中心病例系列和系统综述

Supportive Care in Cancer
IF3
2026-10-150
PRE
Jorge Soriano; Miguel Martínez-Rubiño; Miren Vicente Elcano; Martina Pellicer Pérez; Arantxa  Bergua de Roque; Sofia Tanco Mulero; Claudia Miquel Bosh; Ana Chen-Ye; Deborah Martín Ruiz; Ines Torras-Vigo; Andres Pellicer-Boiges; Mireia Ble Gimeno; Nil Navarro-Gorro; Laia Carla Belarte-Tornero; Laura Visa; Álvaro Taus; Jose Enrique Rodriguez Martínez; Alejo Rodriguez-Vida; Edurne Arriola; Mariona Llaberia-Torrelles
Time to metastasis as a prognostic factor in metastatic urothelial carcinoma: results from the ARON-2 study

转移时间作为转移性尿路上皮癌的预后因素：ARON-2研究的结果

Clinical & Experimental Metastasis
IF3.2
2025-11-210
PRE
Renate Pichler; Gerald Klinglmair; Kirstin Binz; Enrique Grande; Alina Pirshtuk; Hideki Takeshita; Yüksel Ürün; Javier Molina-Cerrillo; Zin W. Myint; Alfonso Gómez de Liaño; Augusto Mota; Alessia Salfi; Wataru Fukuokaya; Enrico Sammarco; Martin Angel; Jakub Kucharz; Deniz Tural; Ondřej Fiala; Alejo Rodriguez-Vida; Franco Morelli; Alexandr Poprach; Mobin Safi; Alvaro Pinto; Francesco Massari; Sebastiano Buti; Shilpa Gupta; Fernando Sabino Marques Monteiro; Andrey Soares; Nicola Battelli; Ravindran Kanesvaran; Matteo Santoni
Age-related Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy and Docetaxel in Patients with Metastatic Hormone-sensitive Prostate Cancer: A Subgroup Analysis of the Phase 3 ARASENS Trial

年龄相关的达罗他胺联合雄激素剥夺疗法和多西他赛在转移性激素敏感前列腺癌患者中的疗效与安全性：一项ARASENS III期试验的亚组分析

European Urology Oncology
IF9.3
2025-11-040
OAAI
Joan Carles; Bertrand Tombal; Maha Hussain; Fred Saad; Karim Fizazi; Álvaro Montesa Pino; Maria José Méndez-Vidal; Alejo Rodriguez-Vida; Daniel Castellano; Pablo Borrega; Patrick Adorjan; Cristina Moretones; Manjari Dissanayake; Matthew R. Smith
Corrigendum to “Development and independent validation of a prognostic gene expression signature based on RB1, PTEN, and TP53 in metastatic hormone-sensitive prostate cancer patients” [Eur. Urol. Oncol. 7 (2024) 954–964]

勘误：关于“基于RB1、PTEN和TP53在转移性激素敏感性前列腺癌患者中开发并独立验证预后基因表达签名”[Eur. Urol. Oncol. 7 (2024) 954–964]

European Urology Oncology
IF9.3
2025-05-010
PRE
Natalia Jiménez; Marta Garcia de Herreros; Òscar Reig; Mercedes Marín-Aguilera; Caterina Aversa; Laura Ferrer-Mileo; Samuel García-Esteve; Leonardo Rodríguez-Carunchio; Isabel Trias; Albert Font; Alejo Rodriguez-Vida; Miguel Ángel Climent; Sara Cros; Isabel Chirivella; Montserrat Domènech; Mariona Figols; Joan Carles; Cristina Suárez; Daniel Herrero Rivera; Enrique González-Billalabeitia; Claudia Cívico; Núria Sala-González; Vicenç Ruiz de Porras; Maria J. Ribal; Aleix Prat; Begoña Mellado
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
CLINICAL CANCER RESEARCH
IF10.2
2024-10-300
OAAI
Flechon, Aude; Morales-Barrera, Rafael; Powles, Thomas; Alva, Ajjai; Ozguroglu, Mustafa; Csoszi, Tibor; Loriot, Yohann; Rodriguez-Vida, Alejo; Geczi, Lajos; Cheng, Susanna Y.; Fradet, Yves; Oudard, Stephane; Vulsteke, Christof; Gunduz, Seyda; Mamtani, Ronac; Yu, Evan Y.; Montesa Pino, Alvaro; Anido, Urbano; Sendur, Mehmet A. N.; Gravis, Gwenaelle; Revesz, Janos; Kostorov, Vladimir; Huillard, Olivier; Ma, Junshui; Rajasagi, Mohini; Vajdi, Amir; Lunceford, Jared; Cristescu, Razvan; Imai, Kentaro; Homet Moreno, Blanca; Matsubara, Nobuaki
First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naive prostate cancer (mHNPC)

ZZFIRST研究初步结果：一项关于恩扎卢胺（EZ）联合或不联合他拉唑帕尼（TALA）治疗转移性激素未治前列腺癌（mHNPC）的随机II期临床试验。

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Mateo, J.; Castro, E.; Rodriguez-Vida, A.; Mellado Gonzalez, B.; Castellano Gauna, D. E.; Climent Duran, M. A.; Borque Fernando, A.; Saez, M. I.; Herrera Imbroda, B.; Font Pous, A.; Lorente, D.; Planas Morin, J.; Vivancos, A.; Cardona, J.; Guerrero, A.; Perez-Escuredo, J.; Saavedra, J. Zurita; Galceran, J. C.
A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

一项随机多中心开放标签III期试验，比较无症状或轻度症状的去势抵抗性前列腺癌 (mCRPC) 患者的恩扎鲁他胺与镭223 (Ra223) 和恩扎鲁他胺的组合: eortc-gucg 1333/PEACE-3的初步结果

ANNALS OF ONCOLOGY
IF65.4
2024-09-0111
PRE
Gillessen, S.; Choudhury, A.; Saad, F.; Gallardo, E.; Soares, A.; Loriot, Y.; McDermott, R. S.; Rodriguez-Vida, A.; Isaacson, P.; Nole, F.; Cruz, F. J. S. Melo; Roumeguere, T.; Daugaard, K. G.; Yamamura, R.; Lecouvet, F.; Coens, C.; Fournier, B.; Tombal, B.
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study

诱导avelumab，然后进行化学免疫疗法和维持与单独化疗作为顺式不合格转移性尿路上皮癌的一线治疗 (INDUCOMAIN): 一项随机II期研究

ESMO OPEN
IF8.3
2024-09-010
OAAI
Rodriguez-Vida, A.; Valderrama, B. P.; Castellano, D.; Pinto, A.; Mellado, B.; Puente, J.; Climent, M. A.; Domenech, M.; Vazquez, F.; Perez-Gracia, J. L.; Bonfill, T.; Morales-Barrera, R.; Gonzalez-Billalabeitia, E.; Garcia-del-Muro, X.; Maroto, P.; Navarro-Gorro, N.; Juanpere, N.; Juan, O.; Bellmunt, J.
Tumour suppressor gene signature predicts early progression in metastatic hormone-sensitive metastatic prostate cancer (mHSPC) patients

肿瘤抑制基因特征可预测转移性激素敏感性前列腺癌（mHSPC）患者的早期进展

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Garcia De Herreros, M.; Jimenez Blasco, N.; Reig Torras, O.; Ferrer Mileo, L.; Aversa, C.; Garcia-Esteve, S.; Rodriguez-Carunchio, L.; Trias Puigsureda, I.; Padrosa, J.; Fernandez Manas, L.; Marin, M.; Font Pous, A.; Rodriguez-Vida, A.; Climent Duran, M. A.; Cros Costa, S.; Chirivella Gonzalez, I.; Figols Gorina, M.; Mellado Gonzalez, B.
EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) plus pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

EV-302：探索性分析nectin-4表达及对一线恩夫妥单抗 vedotin（EV）联合帕博利珠单抗（P）的应答，在既往未治疗的局部晚期或转移性尿路上皮癌（la/mUC）中

ANNALS OF ONCOLOGY
IF65.4
2024-09-015
PRE
Powles, T. B.; Van der Heijden, M. S.; Gupta, S.; Perez Valderrama, B.; Galsky, M. D.; Bedke, J.; Kikuchi, E.; Hoffman-Censits, J.; Rey, J. P. Maroto; Vulsteke, C.; Iyer, G.; Swami, U.; Shin, S. J.; Rodriguez-Vida, A.; Wozniak, M.; Moreno, B. Homet; Lu, J.; Yu, C.; Hogdal, L.; Loriot, Y.
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients
EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-08-014
OA
Jimenez, Natalia; de Herreros, Marta Garcia; Reig, Oscar; Marin-Aguilera, Mercedes; Aversa, Caterina; Ferrer-Mileo, Laura; Garcia-Esteve, Samuel; Rodriguez-Carunchio, Leonardo; Trias, Isabel; Font, Albert; Rodriguez-Vida, Alejo; Climent, Miguel Angel; Cros, Sara; Chirivella, Isabel; Domenech, Montserrat; Figols, Mariona; Carles, Joan; Suarez, Cristina; Rivera, Daniel Herrero; Gonzalez-Billalabeitia, Enrique; Civico, Claudia; Sala-Gonzalez, Nuria; de Porras, Vicenc Ruiz; Ribal, Maria J.; Prat, Aleix; Mellado, Begona
Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study

223镭治疗的转移性去势抵抗性前列腺癌患者的骨代谢生物标志物和生存率的前瞻性评估: PRORADIUM研究

EUROPEAN UROLOGY ONCOLOGY
IF9.3
2024-06-012
PRE
Romero-Laorden, Nuria; Lorente, David; de Velasco, Guillermo; Lozano, Rebeca; Herrera, Bernardo; Puente, Javier; Lopez, Pedro P.; Medina, Ana; Almagro, Elena; Gonzalez-Billalabeitia, Enrique; Villla-Guzman, Jose Carlos; Gonzalez-del-Alba, Aranzazu; Borrega, Pablo; Lainez, Nuria; Fernandez-Freire, Ana; Hernandez, Amaia; Rodriguez-Vida, Alejo; Chirivella, Isabel; Fernandez-Parra, Eva; Lopez-Campos, Fernando; Pacheco, Maria Isabel; Morales-Barrera, Rafael; Fernandez, Ovidio; Villatoro, Rosa; Luque, Raquel; Hernando, Susana; Castellano, Daniel C.; Castro, Elena; Olmos, David
Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
IF2.8
2024-02-161
OAAI
Robbrecht, Debbie; Grob, Jean-Jacques; Bechter, Oliver; Simonelli, Matteo; Doger, Bernard; Borbath, Ivan; Butler, Marcus O.; Cheng, Tina; Romano, Patricia Martin; Pons-Tostivint, Elvire; Di Nicola, Massimo; Curigliano, Giuseppe; Ryu, Min-Hee; Rodriguez-Vida, Alejo; Schadendorf, Dirk; Garralda, Elena; Abbadessa, Giovanni; Demers, Brigitte; Amrate, Amele; Wang, Hong; Lee, Joon Sang; Pomponio, Robert; Wang, Rui
Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)
BRITISH JOURNAL OF CANCER
IF6.8
2023-12-153
PRE
Font, Albert; Mellado, Begona; Climent, Miguel A.; Virizuela, Juan Antonio; Oudard, Stephane; Puente, Javier; Castellano, Daniel; Gonzalez-del-Alba, Aranzazu; Pinto, Alvaro; Morales-Barrera, Rafael; Rodriguez-Vida, Alejo; Fernandez, Pedro L.; Teixido, Cristina; Jares, Pedro; Aldecoa, Iban; Gibson, Neil; Solca, Flavio; Mondal, Shoubhik; Lorence, Robert M.; Serra, Josep; Real, Francisco X.

研究方向

暂未获取到该数据
R
Rafael Morales‐Barrera
H 指数:32论文数:279被引数:5,016
J
Joaquim Bellmunt
H 指数:106论文数:1,140被引数:6.6万
D
Daniel Castellano
H 指数:72论文数:739被引数:4.0万
C
Cristina Suárez
H 指数:54论文数:376被引数:1.4万
B
Begoña Mellado
H 指数:48论文数:361被引数:1.0万
N
Núria Juanpere
H 指数:18论文数:88被引数:1,015
I
Ignacio Durán
H 指数:54论文数:346被引数:1.6万
Ò
Òscar Reig
H 指数:23论文数:179被引数:1,886
J
Javier Puente
H 指数:31论文数:303被引数:5,103
T
Thomas Powles
H 指数:77论文数:690被引数:3.6万